Linaclotide + Placebo for Linaclotide
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Functional Constipation (FC)
Conditions
Functional Constipation (FC), Chronic Idiopathic Constipation (CIC)
Trial Timeline
Dec 29, 2022 → Sep 2, 2025
NCT ID
NCT05652205About Linaclotide + Placebo for Linaclotide
Linaclotide + Placebo for Linaclotide is a phase 3 stage product being developed by AbbVie for Functional Constipation (FC). The current trial status is completed. This product is registered under clinical trial identifier NCT05652205. Target conditions include Functional Constipation (FC), Chronic Idiopathic Constipation (CIC).
What happened to similar drugs?
0 of 5 similar drugs in Functional Constipation (FC) were approved
Approved (0) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05652205 | Phase 3 | Completed |
Competing Products
20 competing products in Functional Constipation (FC)